A study using plasma samples obtained in the JACCRO GC-08 study
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000043051
- Lead Sponsor
- Japan Clinical Cancer Research Organization (JACCRO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 501
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who declined to participate in the "Observational Study of Nivolumab in Unresectable Advanced Gastric Cancer with Biomarker Discovery in Patients with Advanced Unresectable Gastric Cancer (DELIVER): JACCRO GC-08".
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between soluble PD-L1, soluble PD-1, and soluble CTLA-4 before nivolumab treatment and progression-free survival in patients with unresectable advanced gastric cancer
- Secondary Outcome Measures
Name Time Method Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and efficacy (overall survival, response rate, hyper progressive disease) and safety before nivolumab treatment in patients with unresectable advanced gastric cancer Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and clinical background factors Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and efficacy (progression-free survival, overall survival,